RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Thrombotic Thrombocytopenic Purpura: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.
Postmus Tim et al., Blood advances (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42431609/
- 2.
Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study
Adis Journals on behalf of: et al., Figshare (12 October 2026)
https://doi.org/10.6084/m9.figshare.33306591
- 3.
Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study.
Padhiar Amie et al., Advances in therapy (9 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42853532/
- 4.
Right-Sided Colonic Wall Thickening on Abdominal Computed Tomography as a Potential Adjunctive Imaging Clue in Thrombotic Microangiopathy Presenting With Gastrointestinal Symptoms
Koichi Kitamura et al., Cureus (7 October 2026)
https://doi.org/10.7759/cureus.117615
- 5.
From Platelet-Transfusion Risk to the Decision That Matters in Thrombotic Thrombocytopenic Purpura.
Debnath Manti et al., European journal of haematology (7 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42841224/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
NCT02553317 · Completed · Phase 3 · Ablynx, a Sanofi company
Ages 18 and over
https://clinicaltrials.gov/study/NCT02553317
- 2.
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT01151423 · Completed · Phase 2 · Ablynx, a Sanofi company
Ages 18 and over
https://clinicaltrials.gov/study/NCT01151423
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura is a rare blood disorder in which tiny clots form in small blood vessels, using up platelets and damaging organs such as the brain, heart and kidneys. It is caused by a severe lack of an enzyme called ADAMTS13, usually because the immune system attacks it, and less often because of an inherited gene change. Treatment includes plasma exchange, immune-suppressing medicines and newer targeted therapies.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that is caused by a deficiency of a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13). Most patients with TTP have immune-mediated TTP (iTTP), for which the loss of activity results from the development of autoantibodies directed toward ADAMTS13. Preemptive treatment of iTTP with rituximab when ADAMTS13 activity drops to ∼20% (ie, an "ADAMTS13 relapse") can effectively prevent clinical relapse. Nevertheless, patients still undergo prolonged periods of low ADAMTS13 activity. We used unbiased mass spectrometry-based plasma profiling to study alterations in protein levels in a cohort of patients with iTTP treated with elective rituximab. Protein levels in samples obtained during an ADAMTS13 relapse, after the recovery of ADAMTS13 activity, during follow-up in remission, and during a subsequent ADAMTS13 relapse were measured. When comparing the plasma profiles of all patients during ADAMTS13 relapse and remission, signatures associated with the upregulation of hemolysis and platelet activation were observed. These findings show that biological pathways linked to the onset of acute TTP are upregulated in patients with iTTP with ADAMTS13 deficiency before any clinical or routine biochemical changes are observed.
Common Questions
What is Thrombotic Thrombocytopenic Purpura?
Thrombotic thrombocytopenic purpura is a rare blood disorder in which tiny clots form in small blood vessels, using up platelets and damaging organs such as the brain, heart and kidneys. It is caused by a severe lack of an enzyme called ADAMTS13, usually because the immune system attacks it, and less often because of an inherited gene change. Treatment includes plasma exchange, immune-suppressing medicines and newer targeted therapies.
How many clinical trials are available for Thrombotic Thrombocytopenic Purpura?
RareWays currently indexes 35 clinical trials for Thrombotic Thrombocytopenic Purpura, of which 4 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Thrombotic Thrombocytopenic Purpura come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Thrombotic Thrombocytopenic Purpura.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.